Update on the European Vasculitis Study Group trials

Current Opinion in Rheumatology

Volumn 13, Issue 1, 2001, Pages 48-55

  Jayne, David ^a  

^a ST HELIER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; PSEUDOMONIC ACID; THYMOCYTE ANTIBODY;

ARTICLE; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; EUROPE; HUMAN; INFECTION; KIDNEY DISEASE; LEUKOPENIA; PLASMAPHERESIS; POLYARTERITIS NODOSA; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; VASCULITIS;

CLINICAL TRIALS; EUROPE; HUMANS; MULTICENTER STUDIES; VASCULITIS;

EID: 0035170339     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200101000-00008     Document Type: Article

References (69)

1. Autoimmunity in Wegener's granulomatosis
2. Autoantibodies against neutrophils and monocytes: Tool for diagnosis and marker of disease activity in Wegener's granulomatosis
3. Anti-neutrophil cytoplasm antibodies 1988
4. Development and standardization of solid phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA): A report on the second phase of an international cooperative study on the standardization of ANCA assays
5. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization
6. International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA)
7. Nomenclature of systemic vasculitides: Proposal of an international consensus conference
8. The renal histopathology in systemic vasculitis: An international survey study of inter- and intra-observer agreement
9. European therapeutic trials in ANCA-associated systemic vasculitis: Disease scoring, consensus regimens and proposed clinical trials
10. Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis
11. Pathogenesis of ANCA-associated systemic vasculitis
12. VITAL (Vasculitis Integrated Assessment Log) assessment of vasculitis
13. Disease assessment and management of the vasculitides
14. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis
15. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection
16. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides
17. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity
18. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis
19. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis
20. Infectious risk of plasma donations: Relationship to safety of intravenous immune globulins
21. Shortage of intravenous immunoglobulin
22. Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: Initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group
23. Cyclophosphamide therapy of severe systemic necrotizing vasculitis
24. Wegener's granulomatosis: Prospective clinical and therapeutic experience with 85 patients for 21 years
25. Wegener granulomatosis: An analysis of 158 patients
26. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wagener granulomatosis
27. Induction of remission in Wegener's granulomatosis with low dose methotrexate
28. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone
29. Treatment of non-life threatening Wegener's granulomatosis with methotrexate and daily prednisone as the initial therapy of choice
30. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis
31. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement
32. A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis
33. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies
34. Long-term outcome after immunosuppression and plasma exchange for severe vasculitis-associated glomerulonephritis
35. ANCA and predicting relapse in systemic vasculitis
36. Randomized trial of cyclophosphamide versus azathioprine during remission in ANCA-associated vasculitis (CYCAZAREM)
37. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre
38. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis: A prospective, randomized trial in sixty-two patients
39. Plasma exchange and cyclosporin A in Wegener's granulomatosis: A controlled study
40. Plasma exchange and immunosuppression in rapidly progressive glomerulonephritis: A controlled, multi-center study
41. Pulmonary-renal syndrome
42. Association of IgM with IgG ANCA in patients presenting with pulmonary hemorrhage
43. Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy
44. Compassionate treatment of Wegener's granulomatosis with rabbit anti-thymocyte globulin
45. Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: Comparison of steroids and oral or pulse cyclophosphamide in 25 patients
46. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome: A prospective study in 342 patients
47. Reduced gonadal toxicity after i.v. cyclophosphamide administration in patients with nonmalignant diseases
48. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: A prospective, randomized study
49. Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide
50. Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis
51. Intravenous pulse versus oral administration of cyclophosphamide: Comment on the article by Haubitz et al
52. To pulse or not to pulse in ANCA-associated vasculitis - A critical analysis
53. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis
54. Outcome analysis of patients with vasculitis associated with antineutrophil cytoplamic antibodies
55. Histopathological analysis and correlation with renal functioning of biopsies in ANCA-associated systemic vasculitis
56. Relationship between disease activity and anti-neutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis
57. Kidney biopsy as a predictor for renal outcome in ANCA-associated necrotizing glomerulonephritis
58. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis
59. Validity of a vasculitis activity index for systemic necrotizing vasculitis
60. Vasculitis assessment for clinical trials
61. Long-term follow-up of polyarteritis nodosa, microscopic polyangiitis and Churg Strauss syndrome: Analysis of 4 prospective trials including 278 patients
62. Are circulating neutrophils intravascularly activated in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides?
63. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: A pilot study in 11 patients with renal involvement
64. Treatment of acute c-ANCA-positive vasculitis with mycophenolate mofetil
65. Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analyis of three randomized, double-blind, clinical studies in prevention of rejection
66. Acute allergic reactions associated with azathioprine
67. Relapse of vasculitis, sepsis, or azathioprine allergy?
68. Clinical evaluation of a capture ELISA for detection of proteinase-3 antineutrophil cytoplasmic antibody
69. Maintenance of remission with leflunomide in Wegener's granulomatois